Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22165799 | 0.74 | KDM4E (0.37) | ALOX15ALOX12MEN1KMT2AESR1 | |
| SCHEMBL9432036 | 0.73 | GAA (0.36) | ALOX15ALOX12DAOMEN1KMT2A | |
| SCHEMBL22165344 | 0.71 | HSD17B10 (0.37) | ALOX15ALOX12MEN1KMT2AKDM4E | |
| SCHEMBL5533494 | 0.70 | KDM4E (0.42) | MEN1KMT2AKDM4EALDH1A1POLB | |
| Iodide SCHEMBL30896441 | 0.69 | HSD17B10 (0.36) | ALOX15ALOX12MEN1KMT2AKDM4E | |
| SCHEMBL1760478 | 0.67 | ALOX15 (0.54) | ALOX15ALOX12MEN1KMT2AESR1 | |
| SCHEMBL5676149 | 0.67 | ALOX15 (0.68) | ALOX15ALOX12MEN1KMT2AESR1 | |
| SCHEMBL10392532 | 0.67 | NOS3 (0.39) | ALOX15GRM1ALDH1A1 | |
| SCHEMBL10737118 | 0.67 | KDM4E (0.39) | ALOX15ALOX12MEN1KMT2AKDM4E | |
| SCHEMBL860788 | 0.67 | KMT2A (0.76) | ALOX12DAOMEN1KMT2AGRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3902796-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | Nexys Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113348167-A | (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer | 奈可萨斯医药有限公司 | 2021-09-03 | — | — | CN | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139636-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | ALOX15 721/4885ALOX12 1194/4885DAO 1408/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | ALOX15 513/4885ALOX12 1058/4885DAO 1989/4885 |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | TGFBR1, TGFBR2, ACVR1 | ALOX15 721/4885ALOX12 1194/4885DAO 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.